India’s Commerce Secretary Urges Shift From Low‑cost Generic Hub to Global Quality Pharma Leader

Why It Matters

The shift from a volume‑focused, low‑cost model to a quality‑centric strategy could redefine India’s role in global health security. By producing high‑standard biologics and biosimilars, India can reduce dependence on traditional suppliers, mitigate supply‑chain shocks, and meet rising demand for advanced therapies. For multinational buyers, a reliable Indian source of quality medicines offers cost savings without compromising safety, potentially reshaping pricing dynamics in regulated markets. Domestically, the pivot promises higher value‑added jobs, stronger R&D ecosystems, and greater foreign investment. If the sector reaches the $130 bn target, it would outpace many traditional pharma powerhouses, reinforcing India’s position as a third‑tier hub that competes on both price and quality.

Key Takeaways

• Commerce Secretary Rajesh Agrawal calls for India to become a quality‑focused, cost‑effective pharma exporter.
• India’s pharma sector is valued at $60 bn; exports reached $28 bn in FY‑2025/26, up 5.6 % YoY.
• Target: $130 bn in pharma exports by 2030, driven by biologics, biosimilars, and innovation.
• West Asia crisis has disrupted imports of intermediates, prompting diversification and priority status for pharma.
• Over 60 % of Indian pharma exports go to highly regulated markets, indicating existing quality compliance.

Pulse Analysis

India’s new quality narrative aligns with a broader global trend where regulators and buyers are tightening standards for critical medicines. Historically, the country’s competitive advantage lay in scale and low production costs, but margin compression and price erosion in the generic segment have forced a strategic rethink. By leveraging its massive manufacturing base while upgrading quality controls, India can move up the value chain, capturing premium segments that are less vulnerable to price wars.

The policy emphasis on biologics and biosimilars is particularly prescient. Global demand for these products is projected to double by 2035, and the United States alone is expected to spend $200 bn annually on biologics. Indian firms that master the complex manufacturing processes and meet stringent FDA and EMA requirements could secure long‑term contracts, stabilising revenue streams and attracting deeper foreign direct investment.

However, the transition will require substantial capital infusion in quality assurance, regulatory expertise, and talent development. The government’s promise of streamlined approvals and increased R&D funding must translate into actionable incentives. If executed well, India could emerge as a dual‑model exporter—offering both affordable generics and high‑quality specialty drugs—thereby reshaping global supply dynamics and enhancing its geopolitical leverage in health diplomacy.